Journey Medical (DERM) Cash from Investing Activities (2020 - 2023)

Journey Medical has reported Cash from Investing Activities for 4 years, with the latest figure at -$5.0 million in Q1 2023.

• For the quarter ending Q1 2023, Cash from Investing Activities rose 75.0% year-over-year to -$5.0 million; the trailing twelve-month figure through Dec 2023 stood at -$5.0 million (up 75.0% YoY), and the FY2024 full-year result was -$15.0 million, down 200.0% from the prior year.
• Cash from Investing Activities for Q1 2023 stood at -$5.0 million, up from -$20.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$200000.0 in Q4 2020, with the low at -$20.0 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$6.6 million across 4 years, with a median of -$3.1 million in 2021.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities slumped 500.0% — and 2023, when it jumped 75.0%.
• Journey Medical's Cash from Investing Activities stood at -$200000.0 in 2020, then tumbled by 500.0% to -$1.2 million in 2021, then sank by 1566.67% to -$20.0 million in 2022, then jumped by 75.0% to -$5.0 million in 2023.
• The last three Cash from Investing Activities figures came in at -$5.0 million (Q1 2023), -$20.0 million (Q1 2022), and -$1.2 million (Q4 2021), per Business Quant data.